AstraZeneca PLC [NASDAQ: AZN] surged by $0.18 during the normal trading session on Tuesday and reaching a high of $56.94 during the day while it closed the day at $56.73. The company report on November 23, 2021 that HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy.
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET —.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib). The first patient received their first dose on November 22, 2021.
AstraZeneca PLC stock has also loss -1.56% of its value over the past 7 days. However, AZN stock has declined by -3.16% in the 3 months of the year. Over the past six months meanwhile, it has gained 0.34% and gained 13.48% year-on date.
The market cap for AZN stock reached $175.23 billion, with 2.99 billion shares outstanding and 2.60 billion shares in the current float. Compared to the average trading volume of 5.19M shares, AZN reached a trading volume of 5776153 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $69.28 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 12, 2021. The new note on the price target was released on April 12, 2021, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.13, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.34. The Price to Book ratio for the last quarter was 4.27, with the Price to Cash per share for the same quarter was set at 2.31. Price to Free Cash Flow for AZN in the course of the last twelve months was 129.23 with Quick ratio for the last quarter at 0.70.
AZN stock trade performance evaluation
AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.56. With this latest performance, AZN shares dropped by -8.16% in over the last four-week period, additionally plugging by 0.34% over the last 6 months – not to mention a rise of 3.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 31.87, with the RSI for the last a single of trading hit 25.64, and the three-weeks RSI is set at 36.97 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 60.12, while it was recorded at 56.88 for the last single week of trading, and 56.10 for the last 200 days.
AstraZeneca PLC [AZN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +16.98 and a Gross Margin at +74.01. AstraZeneca PLC’s Net Margin is presently recorded at +11.58.
Return on Total Capital for AZN is now 14.29, given the latest momentum, and Return on Invested Capital for the company is 10.66. Return on Equity for this stock inclined to 23.36, with Return on Assets sitting at 5.24. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 130.46. Additionally, AZN Total Debt to Total Capital is recorded at 56.61, with Total Debt to Total Assets ending up at 30.54. Long-Term Debt to Equity for the company is recorded at 115.18, with the Long-Term Debt to Total Capital now at 49.98.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $32,750 per employee. Receivables Turnover for the company is 5.35 with a Total Asset Turnover recorded at a value of 0.45.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.10.
Earnings per share (EPS) analysis for AstraZeneca PLC [AZN] stock
With the latest financial reports released by the company, AstraZeneca PLC posted 0.53/share EPS, while the average EPS was predicted by analysts to be reported at 0.68/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 20.60%.
AstraZeneca PLC [AZN]: Insider Ownership positions
There are presently around $29,831 million, or 17.40% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 82,322,522, which is approximately 18.462% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 53,145,564 shares of the stock with an approximate value of $3.01 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $2.74 billion in AZN stock with ownership of nearly -0.899% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 388 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 52,478,803 shares. Additionally, 707 investors decreased positions by around 411,947,005 shares, while 137 investors held positions by with 61,418,419 shares. The mentioned changes placed institutional holdings at 525,844,227 shares, according to the latest SEC report filing. AZN stock had 78 new institutional investments in for a total of 3,942,681 shares, while 325 institutional investors sold positions of 183,166,286 shares during the same period.